Can Next-Generation PI3K Inhibitors Unlock the Full Potential of the Class in Patients With B-Cell Lymphoma?
Tycel Phillips, Jean‐Marie Michot, Vincent Ribrag
Topics & Concepts
MedicineIdelalisibFollicular lymphomaAdverse effectOncologyPI3K/AKT/mTOR pathwayClinical trialLymphomaTargeted therapyInternal medicinePopulationCancerChronic lymphocytic leukemiaIbrutinibLeukemiaApoptosisEnvironmental healthChemistryBiochemistryChronic Lymphocytic Leukemia ResearchLymphoma Diagnosis and TreatmentMultiple Myeloma Research and Treatments